Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia
Dwight D. Harris, Sharif A. Sabe, Cynthia Xu, Mohamed Sabra, Mark Broadwin, Akshay Malhotra, Janelle W. Li, M. Ruhul Abid, Frank W. Sellke
Topics & Concepts
MedicineCanagliflozinInternal medicineEndocrinologyAcetyl-CoA carboxylaseBeta oxidationPharmacologyInflammationType 2 diabetesIschemiaInsulin resistanceDiabetes mellitusMetabolismPyruvate carboxylaseBiochemistryEnzymeBiologyDiabetes Treatment and ManagementPancreatic function and diabetesCardiovascular Function and Risk Factors